Bastounis, A, Langley, T, Davis, S, Paskins, Z ORCID: https://orcid.org/0000-0002-7783-2986, Gittoes, N, Leonardi-Bee, J and Sahota, O (2022) Assessing the effectiveness of bisphosphonates for the prevention of fragility fractures: an updated systematic review and network meta-analyses. Osteoporosis International, 32 (SUPPL). S270 - S270.

[img]
Preview
Text
JBMR Plus - 2022 - Bastounis - Assessing the effectiveness of bisphosphonates for the prevention of fragility fractures an.pdf - Accepted Version

Download (641kB) | Preview

Abstract

Bisphosphonates have been found to be effective in preventing fragility fractures. However, their comparative effectiveness in populations at risk has yet to be defined. In light of recent clinical trials, we aimed to compare four bisphosphonates (alendronate, ibandronate, risedronate, and zoledronate) and to identify which are the most effective for the prevention of fragility fractures. This is an update of a systematic review previously published as part of a NICE HTA report. We conducted a systematic review and network meta-analysis, updating the estimates regarding the comparative effectiveness of the aforementioned bisphosphonates. Studies identified from published and unpublished sources between 2014 and 2021 were added to the studies identified in the previous review. Screening, data extraction and risk of bias assessment were independently undertaken by two reviewers. Outcomes were fractures, femoral neck bone mineral density (BMD), mortality, and adverse events. We identified 25 additional trials, resulting in a total population of 47,007 participants. All treatments had beneficial effects on fractures versus placebo with zoledronate being the most effective treatment in preventing vertebral fractures HR = 0.38 (95%CrI: 0.28, 0.49). Zoledronate HR = 0.71 (95%CrI: 0.61, 0.81) and risedronate HR = 0.70 (95%CrI: 0.53, 0.84) were found to be the most effective treatments in preventing non-vertebral fractures. All treatments were associated with increases in femoral neck BMD versus placebo with zoledronate being the most effective treatment MD = 4.02 (95%CrI: 3.2, 4.84). There was a paucity of data regarding hip and wrist fractures. Depending on its cost-effectiveness, zoledronate could be considered a first-line option for people at increased risk of fragility fractures.

Item Type: Article
Additional Information: The final version of this accepted manuscript and all relevant information related to it, including copyrights, can be found on the publisher website. This information also appeared as a poster abstract, which can be found at; https://link.springer.com/article/10.1007/s00198-021-06125-9
Uncontrolled Keywords: Antiresorptives; Bisphosphonates; Fracture Prevention; Fractures; Injury; Fracture Healing; Network Meta-analysis; Osteoporosis; Screening; Systematic Review
Subjects: R Medicine > R Medicine (General)
R Medicine > R Medicine (General) > R735 Medical education. Medical schools. Research
R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Related URLs:
Depositing User: Symplectic
Date Deposited: 17 Mar 2022 11:46
Last Modified: 18 May 2022 12:49
URI: https://eprints.keele.ac.uk/id/eprint/10720

Actions (login required)

View Item View Item